Septerna (NASDAQ:SEPN) Shares Gap Down – What’s Next?

Septerna, Inc. (NASDAQ:SEPN)’s share price gapped down before the market opened on Monday . The stock had previously closed at $37.34, but opened at $35.18. Septerna shares last traded at $34.9050, with a volume of 136,353 shares.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Raymond James Financial lifted their target price on Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a research report on Monday, June 8th. Truist Financial lifted their price target on shares of Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Stifel Nicolaus initiated coverage on shares of Septerna in a research note on Friday, May 1st. They issued a “buy” rating and a $43.00 price target on the stock. Wall Street Zen cut shares of Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Septerna in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.78.

Septerna Stock Performance

The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -42.22 and a beta of 2.39. The firm has a 50-day simple moving average of $29.24 and a two-hundred day simple moving average of $27.37.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The business had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, equities analysts forecast that Septerna, Inc. will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Septerna news, insider Samira Shaikhly sold 6,250 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $35.08, for a total transaction of $219,250.00. Following the sale, the insider owned 793 shares in the company, valued at $27,818.44. This represents a 88.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $35.51, for a total transaction of $532,650.00. Following the completion of the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,423,590.12. This trade represents a 13.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 42,983 shares of company stock worth $1,375,607 in the last ninety days. 5.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SEPN. Group One Trading LLC increased its holdings in Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares during the last quarter. Global Retirement Partners LLC acquired a new position in shares of Septerna in the 4th quarter worth approximately $35,000. Russell Investments Group Ltd. bought a new stake in shares of Septerna in the 3rd quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Septerna in the 4th quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Septerna during the 4th quarter valued at approximately $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.